Cancer Chemother Pharmacol (2014) 73:191–198 DOI 10.1007/s00280-013-2340-5
Original Article
Efficacy of concurrent chemoradiotherapy with 5-fluorouracil or gemcitabine in locally advanced biliary tract cancer Seung Woo Yi · Dae Ryong Kang · Kyung Sik Kim · Mi Suk Park · Jinsil Seong · Jeong Youp Park · Seung Min Bang · Si Young Song · Jae Bock Chung · Seung Woo Park
Received: 25 February 2013 / Accepted: 24 October 2013 / Published online: 10 December 2013 © Springer-Verlag Berlin Heidelberg 2013
Abstract Purpose There is no established standard treatment for patients with locally advanced biliary tract cancer (BTC). Methods We analyzed the treatment results of locally advanced BTC from Jan 1995 to Dec 2010 at single institution of South Korea with retrospective study. One hundred and seventy-six patients were eligible to investigate the treatment response and toxicity. We treated these patients with 5-fluorouracil (5-FU)- or gemcitabine (GEM)-based concurrent chemoradiotherapy (CCRT) or best supportive care (BSC). The primary end point was overall survival. Results Of these locally advanced BTC patients, 106 patients received CCRT and 70 patients were treated with BSC. The median overall survival was 42.57 weeks (95 % confidence interval [CI], 35.85–49.30) in CCRT group
S. W. Yi · J. Y. Park · S. M. Bang · S. Y. Song · J. B. Chung · S. W. Park (*) Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, 50 Yonsei‑ro, Seodaemun‑gu, Seoul 120‑752, Republic of Korea e-mail: [email protected] D. R. Kang Biostatistics Collaboration Unit, Yonsei University College of Medicine, Seoul, Republic of Korea K. S. Kim Department of Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea M. S. Park Department of Diagnostic Radiology, Yonsei University College of Medicine, Seoul, Republic of Korea J. Seong Department of Radiation Oncology, Yonsei University College of Medicine, Seoul, Republic of Korea
and 13.29 weeks (95 % CI 10.42–16.15) in BSC group (P
Original Article
Efficacy of concurrent chemoradiotherapy with 5-fluorouracil or gemcitabine in locally advanced biliary tract cancer Seung Woo Yi · Dae Ryong Kang · Kyung Sik Kim · Mi Suk Park · Jinsil Seong · Jeong Youp Park · Seung Min Bang · Si Young Song · Jae Bock Chung · Seung Woo Park
Received: 25 February 2013 / Accepted: 24 October 2013 / Published online: 10 December 2013 © Springer-Verlag Berlin Heidelberg 2013
Abstract Purpose There is no established standard treatment for patients with locally advanced biliary tract cancer (BTC). Methods We analyzed the treatment results of locally advanced BTC from Jan 1995 to Dec 2010 at single institution of South Korea with retrospective study. One hundred and seventy-six patients were eligible to investigate the treatment response and toxicity. We treated these patients with 5-fluorouracil (5-FU)- or gemcitabine (GEM)-based concurrent chemoradiotherapy (CCRT) or best supportive care (BSC). The primary end point was overall survival. Results Of these locally advanced BTC patients, 106 patients received CCRT and 70 patients were treated with BSC. The median overall survival was 42.57 weeks (95 % confidence interval [CI], 35.85–49.30) in CCRT group
S. W. Yi · J. Y. Park · S. M. Bang · S. Y. Song · J. B. Chung · S. W. Park (*) Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, 50 Yonsei‑ro, Seodaemun‑gu, Seoul 120‑752, Republic of Korea e-mail: [email protected] D. R. Kang Biostatistics Collaboration Unit, Yonsei University College of Medicine, Seoul, Republic of Korea K. S. Kim Department of Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea M. S. Park Department of Diagnostic Radiology, Yonsei University College of Medicine, Seoul, Republic of Korea J. Seong Department of Radiation Oncology, Yonsei University College of Medicine, Seoul, Republic of Korea
and 13.29 weeks (95 % CI 10.42–16.15) in BSC group (P
